TÜBINGEN, Germany / BOSTON, MA, February 4, 2019 – CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced today the appointment of Stefan Mueller, Ph.D., as Vice President Preclinical. Dr. Mueller will oversee preclinical programs across CureVac’s pipeline from drug discovery to Investigational New Drug (IND) filing. His appointment augments the recent hiring of Dimitris Voliotis, M.D., Dr. med. as Chief Development Officer and bolsters CureVac’s commitment to aggressively develop and advance assets to help positively transform the lives of patients.
“I am very pleased to welcome Dr. Stefan Mueller to the CureVac team,” said Dr. Dimitris Voliotis, Chief Development Officer, CureVac. “With Dr. Mueller’s expertise in early-stage drug development, we are able to broaden our approach to preclinical programs and determine the best path forward for our naturally optimized mRNA candidates across our oncology, molecular therapy and prophylactic vaccine pipelines.”
Dr. Mueller will be responsible for rapidly advancing CureVac’s preclinical pipeline and will report to Dr. Dimitris Voliotis. Prior to joining CureVac, Dr. Mueller was most recently Global Program Leader for Rituximab biosimilar (Rixathon®) at Sandoz Biopharmaceuticals. Other previous experience includes positions at Merck Serono, Merck, and Knoll GmbH, focusing in the areas of toxicology, drug discovery, and early drug development. Dr. Mueller was awarded his Ph.D. from University of Würzburg in 1997.
“It is an honor to join CureVac during this exciting time in the field of mRNA science,” said Dr. Stefan Mueller, Vice President Preclinical, CureVac. “CureVac is leading the way with its mRNA technology and I look forward to utilizing it to better define preclinical product candidates that advance our mission to revolutionize human health through the unlimited possibilities of mRNA.”
Dr. Mueller joined CureVac on February 1, 2019 and is based at the company’s Tübingen, Germany headquarters.